GSK Pharmaceuticals reported a 29 percent year-on-year increase in net profit for the third quarter, with earnings reaching Rs 296 crore, driven by steady growth in its core therapeutic portfolio and improved operational efficiency. The performance reflects resilient domestic demand, effective cost management, and continued traction in key prescription segments. Revenue expansion and margin stability supported the bottom line, even as the broader pharmaceutical sector navigates pricing pressures and regulatory oversight.